RDAF 2022 General Assembly Meeting

    21 Mar, 2022

    On 21 March 2022, the Rare Disease Action Forum (RDAF) held its annual General Assembly meeting. An overview of the RDAF’s activities in 2021 and an outlook for 2022 were presented. The RDAF President welcomed the new members and underlined that the collaborative approach, which constitutes the core of the RDAF, is essential to identify barriers, raise awareness and work towards an improved framework for rare diseases.

    The General Assembly elected the RDAF Board of Directors: Shayesteh Fürst-Ladani (SFL Pharma), Jasmin Barman-Aksözen (Swiss Society for Porphyria), Rea Lal (Pfizer), Bettina Nauli (Alexion), Jacqueline de Sá (ProRaris), Alessandro Strebel (Roche), Andreas Uttenweiler (Takeda) and Raffaella Willmann (FSRMM). Shayesteh Fürst-Ladani was re-elected as RDAF President.

    Continue reading

    Joint statement on the KVV/OAMal and KLV/OPAS revision

    The RDAF co-signed a joint statement with other stakeholders on the revision of the Health Insurance Ordinance (KVV/OAMal) and Health Benefits Ordinance (KLV/OPAS). The statement highlights the potential negative impacts of the revision, including the following: -...